BCRX logo

BCRX
Biocryst Pharmaceuticals Inc.

36,572
Mkt Cap
$1.86B
Volume
2.6M
52W High
$11.31
52W Low
$6.00
PE Ratio
-158.14
BCRX Fundamentals
Price
$7.45
Prev Close
$7.48
Open
$7.47
50D MA
$7.13
Beta
0.97
Avg. Volume
4.96M
EPS (Annual)
-$0.43
P/B
-4.06
Rev/Employee
$777,089.66
$2,074.71
Loading...
Loading...
News
all
press releases
BioCryst Pharmaceuticals (BCRX) Earnings Expected to Grow: Should You Buy?
BioCryst (BCRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·1d ago
News Placeholder
More News
News Placeholder
BioCryst Pharmaceuticals (BCRX) to Release Earnings on Thursday
BioCryst Pharmaceuticals (NASDAQ:BCRX) will be releasing its Q4 2025 earnings before the market opens on Thursday, February 26. (View Earnings Report at...
MarketBeat·2d ago
News Placeholder
BioCryst Pharmaceuticals (NASDAQ:BCRX) Coverage Initiated at Evercore
Evercore assumed coverage on BioCryst Pharmaceuticals in a research report on Wednesday. They set an "outperform" rating and a $17.00 target price on the stock...
MarketBeat·2d ago
News Placeholder
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Receives Average Recommendation of "Moderate Buy" from Analysts
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Get Free Report) has earned an average rating of "Moderate Buy" from the fourteen analysts that are currently covering the company, MarketBeat.com...
MarketBeat·19d ago
News Placeholder
Royal Bank Of Canada Lowers BioCryst Pharmaceuticals (NASDAQ:BCRX) Price Target to $13.00
Royal Bank Of Canada cut their price target on BioCryst Pharmaceuticals from $14.00 to $13.00 and set an "outperform" rating for the company in a research note on Friday...
MarketBeat·21d ago
News Placeholder
Strength Seen in Korro Bio, Inc. (KRRO): Can Its 13.9% Jump Turn into More Strength?
Korro Bio, Inc. (KRRO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Zacks·21d ago
News Placeholder
BioCryst Pharmaceuticals (NASDAQ:BCRX) Stock Price Up 5.3% - Still a Buy?
BioCryst Pharmaceuticals (NASDAQ:BCRX) Stock Price Up 5.3% - Should You Buy...
MarketBeat·28d ago
News Placeholder
Campbell & CO Investment Adviser LLC Decreases Position in BioCryst Pharmaceuticals, Inc. $BCRX
Campbell & CO Investment Adviser LLC lessened its position in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 73.4% during the 3rd quarter, according to the company in its...
MarketBeat·1mo ago
News Placeholder
BioCryst Pharmaceuticals (NASDAQ:BCRX) Stock Price Down 5.8% - What's Next?
BioCryst Pharmaceuticals (NASDAQ:BCRX) Stock Price Down 5.8% - Here's Why...
MarketBeat·1mo ago
News Placeholder
BioCryst Pharmaceuticals Touts ORLADEYO Momentum, Astria Deal and 2026 Outlook at JPM Conference
BioCryst Pharmaceuticals (NASDAQ:BCRX) outlined a multi-pronged growth strategy at the JPMorgan Healthcare Conference, highlighting continued momentum for its hereditary angioedema (HAE) franchise, a...
MarketBeat·1mo ago
<
1
2
...
>

Latest BCRX News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.